Skip to main content
Clinical Trials/NCT04158921
NCT04158921
Terminated
Not Applicable

Control:Diabetes - a Mobile App to Improve Glycemic Control in Patients With Diabetes

Brigham and Women's Hospital1 site in 1 country55 target enrollmentNovember 7, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Insulin Treated Type 2 Diabetes Mellitus
Sponsor
Brigham and Women's Hospital
Enrollment
55
Locations
1
Primary Endpoint
The mean change in blood glucose.
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

This is a single arm open label pilot clinical trial that will assess patient-reported blood glucose levels before and after using the Control:Diabetes mobile app, while collecting user feedback and recommendations for further improvements to the app functionality and user interface. This study will enroll approximately 70 individuals with insulin-treated diabetes mellitus. The study will include two online surveys (baseline and exit), one study initiation phone call, and will also collect data entered by the users into the mobile app.

Detailed Description

The objectives of this study are to: * Test the hypothesis that patients with diabetes mellitus treated with insulin and elevated blood glucose will achieve better glycemic control after using the Control:Diabetes mobile app. * Test the hypothesis that patients with diabetes mellitus treated with insulin and frequent hypoglycemia will achieve lower frequency of hypoglycemia after using the Control:Diabetes mobile app.

Registry
clinicaltrials.gov
Start Date
November 7, 2019
End Date
July 20, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Alexander Turchin

Associate Professor of Medicine

Brigham and Women's Hospital

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years
  • Diagnosis of Type 1 Diabetes or Type 2 Diabetes
  • Treatment with multiple daily insulin injections (MDII) or continuous subcutaneous insulin infusion (CSII)
  • Baseline HbA1c between 7% and 10.5% (as reported by the participant) and/or self- reported frequency of symptomatic hypoglycemia ≥ 3 times / week
  • Ownership of a smartphone running either Android or iOS operating system with an active data plan

Exclusion Criteria

  • Using a closed loop insulin delivery system (Medtronic 670G or OpenAPS)

Outcomes

Primary Outcomes

The mean change in blood glucose.

Time Frame: Measured between the first two weeks and the last two weeks of the study.

As recorded by the patient in the app.

Secondary Outcomes

  • The change in the number of hypoglycemic episodes.(Measured every week between the two weeks prior to the study entry and the last two weeks of study follow-up.)

Study Sites (1)

Loading locations...

Similar Trials